On July 2, Oklo Inc. rose 5.45% in regular trading, trading at $55.58/share, with turnover of approximately $108 million.

On the news front, the company announced that its Groves Isotope Test Reactor located in Texas has received final safety basis document approval from the US Department of Energy, covering technical analysis of potential hazards, safety controls, and operating requirements needed to support safe startup. The approval transitions Groves from the documentation phase into final pre-startup review, with only readiness review and startup approval remaining. Following startup approval, the facility will be authorized to receive and load nuclear fuel, conduct startup testing, and proceed toward first criticality. The company is targeting first criticality this month.

This milestone builds on a series of recent catalysts, including DOE approval of the preliminary documented safety analysis for the Aurora powerhouse at Idaho National Laboratory, acquisitions of ARMEC and Creative Engineers to strengthen supply chain vertical integration, and a letter of intent with Centrus Energy for high-assay low-enriched uranium supply starting in 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)